Resflor 100ml Treatment of respiratory infections caused by Mannheimia haemolytica, Pasteurella multocida, Resflor 100ml Mycoplasma bovis and Histophilus somni associated with pyrexia. Resflor contains Florfenicol and Flunixin to provide an antibiotic and anti inflammatory and anti pyrexic in one dose.
Resflor 100ml Treatment of respiratory infections caused by Mannheimia haemolytica, Pasteurella multocida, Resflor 100ml Mycoplasma bovis and Histophilus somni associated with pyrexia. Resflor contains Florfenicol and Flunixin to provide an antibiotic and anti inflammatory and anti pyrexic in one dose.Resflor 100ml
Resflor 300/16.5 mg/ml Solution for Injection for Cattle.
Qualitative and quantitative composition
For a full list of excipients, see section “Pharmaceutical Particulars”.
Solution for injection. Clear, light yellow to straw coloured liquid.
Indications for use
Curative treatment of respiratory infections caused by Mannheimia haemolytica, Pasteurella multocida and Histophilus somni associated with pyrexia.Resflor 100ml
Do not use in adult bulls intended for breeding purposes. Do not use in animals suffering from hepatic and renal diseases. Do not use if there is a risk of gastrointestinal bleeding or in cases where there is evidence of altered haemostasis. Do not use in animals suffering from cardiac diseases. Do not use in the case of known hypersensitivity to active substances or to any of the excipients.
Special warnings for each target species
Special precautions for use
The product should be used in conjunction with susceptibility testing and take into account official and local antimicrobial policies. Avoid use in dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of increased renal toxicity. Concurrent administration of potentially nephrotoxic drugs should be avoided.
Repeated daily dosing has been associated with abomasal erosions in the pre-ruminant calf. The product should be used with caution in this age group. The safety of the product has not been tested in calves of 3 weeks of age or less.
Care should be taken to avoid accidental self-injection. Wash hands after use. Do not use the product in known cases of sensitivity to propylene glycol and polyethylene glycols.
Subcutaneous administration of the product may result in injection site swellings that become palpable 2-3 days after injection. The duration of the injection site swellings ranged from 15-36 days post-injection. Grossly, this is associated with minimal to mild irritation of the subcutis. Extension into the underlying muscle was noted in only a few instances. By 56 days post-dosing, no gross lesions were observed that would require any trim-out at slaughter.
Use during pregnancy, lactation or lay
The effect of florfenicol on bovine reproductive performance, pregnancy and lactation has not been assessed. Use only accordingly to the benefit/risk assessment by the responsible veterinarian.
Concurrent use of other active substances that have a high degree of protein binding may compete with flunixin for binding and thus lead to toxic effects. Pre-treatment with other anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before the commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously. The product must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Gastrointestinal tract ulceration may be exacerbated by corticosteroids in animals given NSAIDs.
Amounts to be administered and administration route
40 mg/kg florfenicol and 2.2 mg/kg flunixin (2 ml/15 kg body weight) to be administered by a single subcutaneous injection. To ensure correct dosage and avoid under dosing, bodyweight should be determined as accurately as possible. The dose volume given at any one injection site should not exceed 10 ml. It is recommended to treat animals in the early stages of the disease and to evaluate the response to treatment 48 hours after injection. The anti-inflammatory component of Resflor, flunixin, may mask a poor bacteriological response to florfenicol in the first 24 hours after injection. If clinical signs of respiratory disease persist or increase, or if relapse occurs, treatment should be changed, using another antibiotic, and continued until clinical signs have resolved. The injection should only be given in the neck. Swab septum before removing each dose. Use a dry sterile needle and syringe.